Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NicOx and Topigen have mutually terminated their collaboration for TPI 1020. The decision was made as a result of the acquisition of Topigen by Pharmaxis.
Subscribe to our email newsletter
Following two phase 2a studies that were conducted by Topigen with TPI 1020 in patients with asthma and COPD, NicOx and Topigen had recently been in active discussions to explore potential new opportunities for the development of TPI 1020 in a variety of respiratory indications. As a result of the strategic review of Pharmaxis and Topigen’s development pipeline, they have decided not to move forward with the development of TPI 1020.
The licensing and co-development agreement between NicOx and Topigen on TPI 1020, a novel anti-inflammatory drug-candidate for respiratory indications, was signed in October 2005.
NicOx is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Chemical Entities (NCEs), for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.